v3.26.1
Schedule of Deferred Tax Assets and Liabilities (Details) - Titan Pharmaceuticals Inc [Member] - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Net operating loss carryforwards $ 45,516 $ 49,611
Research credit carryforwards 8,731 9,214
Other, net 895 1,655
Total deferred tax assets 55,142 60,480
Other, net
Total deferred tax liabilities
Valuation allowance (55,142) (60,480)
Net deferred tax assets